ACTRN12619000375156已完成1 期
A randomised, controlled phase 1 study to investigate the safety and efficacy of orally administered squalamine in subjects with Motor Neuron Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Clinically definite or clinically probable MND defined according to the revised El Escorial criteria
- •-Age >18 years
- •-Provision of informed consent from the patient
- •-Willingness to give written informed consent and willingness to comply with the study
排除标准
- •-Inability of patient to provide consent
- •-Inability to swallow capsules
- •-Participation in another/other clinical trials
- •-Prohibited concomitant medications: antibiotics, probiotics
研究者
相似试验
已完成
1 期
A Phase I study to assess Reactogenicity, safety and immunogenicity of Biological E’s Liquid Hexavalent Vaccine when administered in healthy children of 16 to 24 months.CTRI/2023/05/052319Biological E.Limited48
尚未招募
不适用
A mobile health application for people in remote and rural Queensland who have experienced a cardiovascular event.Coronary Heart DiseaseCardiovascular - Coronary heart diseaseCardiovascular diseaseACTRN12621001229864Menzies Health Institute Queensland (MHIQ)60
进行中（未招募）
1 期
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsEUCTR2020-004741-37-BEGlaxoSmithKline Biologicals1,258
进行中（未招募）
1 期
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsHealthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)EUCTR2020-004741-37-FIGlaxoSmithKline Biologicals1,379
进行中（未招募）
1 期
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsHealthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)EUCTR2020-004741-37-PLGlaxoSmithKline Biologicals1,379